CliffBio
biologic

Tivdak

tisotumab vedotin-tftv

Loss of exclusivitySeptember 2033projected — 12-year biologic exclusivity estimate
CompanySeagen →View the full company profile on CliffBio

Drug detail

Brand nameTivdak
Active ingredienttisotumab vedotin-tftv
Strength40MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2021
Marketing statusRx

More from Seagen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tivdak patent cliff — loss of exclusivity September 2033 | CliffBio